Clinically Researched
Science-based Ingredients
Patented Formulations
Designed for Eye Health
Commitment to Innovation,
Transparency & Quality
MaculaPM™
Support Macula & Retina Health
MaculaPM™ is a critical dietary supplement that has been formulated to support eye health for those at risk for AMD (Age Related Macular Degeneration) and those diagnosed with dry AMD. MaculaPM™ contains L-DOPA - a natural product of the velvet bean called mucuna puriens, melatonin, and other key ingredients found to be protective against AMD in clinical trials and basic research.
Years of research have led to the development of MaculaPM™. As we age, the retina slows down the production of L-DOPA, so researchers have been able to conclude that by taking L-DOPA supplementation - the critical ingredient in MaculaPM™ - individuals are able to reduce the progression from dry AMD to the more serious form of the disease, wet AMD.
MaculaPM™ Ingredients
Proactive Eye Health for Your Macula & Retina
L-DOPA
The key ingredient in MaculaPM™ has been shown in a clinical trial to slow the progression to Wet AMD.
Vitamin C
Vitamin C is an anti-oxidant that supports eye health that naturally reduces in concentration with age.
Vitamin E
Vitamin E is a potent anti-oxidant that supports eye health.
Melatonin
Melatonin has been shown to protect retinal pigment epithelium (RPE) cells from oxidative damage.
Lutein
Lutein works as an antioxidant that protects the eye from the effects of aging and ultraviolet light.
Zeaxanthin
Research shows that Zeaxanthin helps to reduce AMD progression and may improve visual acuity.
Learn More About How the MaculaPM™ Formulation Acts to Protect the Macula from AMD
Patient Testimonial
This patient has been taking L-DOPA and Melatonin supplements (the key ingredients in the MaculaPM™ formulation) for over 10 years.
L-DOPA & Melatonin Research
Dr. Snyder discusses the clinical research related to the use of Melatonin and L-Dopa for patients concerned about AMD (age-related macular degeneration.)
The Origin of MaculaPM
John Marten shares the origin story for MaculaPM™, recalling how genetic research into causes and prevention of blindness led to the creation of MaculaPM™.
About Tech Launch Arizona
The University of Arizona is a place of learning, invention and discovery. Tech Launch Arizona collaborates with creators and the local community to help bring those discoveries to the world through commercial pathways. MaculaPM benefited from research conducted at the University of Arizona and licensed the formulation from Tech Launch Arizona.
Meet the Medical Team Behind MaculaPM™
Robert W. Snyder, MD, PhD, PC
Dr. Snyder has extensive clinical ophthalmologic experience as well as a PhD in microbiology/cell biology. He has received peer reviewed funding for both clinical research and trials, as well as basic research. He served as the Chairman of Ophthalmology at The University of Arizona where he received numerous grants, conducted clinical trials, and secured NIH funding for eye research.
Dr. Brian McKay
Dr. McKay is a leading researcher with extensive experience in ophthamology, macular degeneration and other vision-related research. Dr. McKay earned his Ph.D. at the Medical College of Wisconsin. He also received postdoctoral training at The Scripps Institute, and he currently serves as a course director in the vision science colloquium at the University of Arizona.
John A. Martens
With degrees in Chemical Engineering and Chemistry, John Martens has decades of experience as a scientist, engineer and product innovator. He served as a corporate scientist for 35 years at 3M Corporation, and he has been involved in the development of products and technologies for numerous nutraceutical, pharmaceutical and biomedical products related to the treatment of eye diseases.
Dr. Murray H. Brilliant
Dr. Brilliant has a degree in Biology and received his doctorate in Molecular Cell & Developmental Biology. He is currently a professor of Ophthalmology at the University of Arizona where he has a research focus in areas related to macular degeneration. Dr. Brilliant headed the research project that identified the profound protective benefits of L-DOPA on age-related macular degeneration.
